Zika Virus
The Indian Council of Medical Research (ICMR) has inked agreements with multiple stakeholders for the first in-human clinical trials (Phase I) for four promising molecules including a vaccine for Zika virus. These include collaborative research over a small molecule for multiple myeloma with Aurigene Oncology Limited, partnering for Zika vaccine development with Indian Immunologicals Limited, coordinating seasonal Influenza virus vaccine trial with Mynvax Private Limited, and CAR-T cell therapy advancement study for a new indication of chronic lymphocytic leukemia with ImmunoACT.
The apex research body said the initiative is a crucial step towards establishing India as a leader in the clinical development of pharmaceutical agents. “This collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships. Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions,” said Dr. Rajiv Bahl, Secretary, Department of Health Research & Director General, ICMR.
Union health minister J P Nadda, commended the strategic collaboration between ICMR and prominent industry and academic partners, emphasizing it as a key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens. He noted that this initiative positions India to emerge as a global leader in healthcare innovation.
The ICMR Network for Phase 1 Clinical Trials comprises four strategically located institutions across India—KEMH & GSMC, Mumbai; ACTREC, Navi Mumbai; SRM MCH&RC, Kattankulathur; and PGIMER, Chandigarh—supported by a Central Coordinating Unit at ICMR Headquarters, New Delhi. This network is designed to build and enhance India’s capacity to conduct early-phase clinical trials, supported by robust infrastructure and dedicated manpower at each trial site, ensuring smooth and effective operations.
The signing of these agreements reinforces the strong partnerships ICMR has cultivated with key industry players. It underscores the institute’s dedication to building a robust clinical trial ecosystem in India, fostering capacity to develop new drugs from early-phase trials through to marketing, thereby reducing dependency on international resources, and ultimately driving the mission of affordable, high-quality healthcare for all.
Doctors at AIIMS Delhi have successfully performed a rare and technically demanding lung-preserving surgery on…
Sharda Hospital successfully performed a rare scarless surgery to remove a massive benign facial tumor…
A 29-year-old woman with a severe post-burn deformity of the left chest and breast, resulting…
Zydus Lifesciences with Guardant Health, having an agreement to make the Shield™ Multi-Cancer Detection (MCD)…
In the backdrop of observation that India may emerge as the Cancer Capital of the…
The Centre has amended the Drugs rule, omitting the word “Syrup” from Schedule K, the…